Tomoyuki Nishikawa
Overview
Explore the profile of Tomoyuki Nishikawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chang C, Sun J, Hayashi H, Suzuki A, Sakaguchi Y, Miyazaki H, et al.
AAPS PharmSciTech
. 2019 Dec;
21(1):19.
PMID: 31820256
DNA vaccination can be applied to the treatment of various infectious diseases and cancers; however, technical difficulties have hindered the development of an effective delivery method. The efficacy of a...
12.
Tai J, Chang C, Nishikawa T, Kaneda Y
Cancer Gene Ther
. 2019 Aug;
27(6):498-508.
PMID: 31383952
Inactivated Sendai virus particle (or hemagglutinating virus of Japan envelope; HVJ-E) has been previously reported to possess antitumour properties that activate antitumour immunity. Two glycoproteins, fusion (F) and hemagglutinin-neuraminidase (HN),...
13.
Inai M, Honda N, Hazama H, Akter S, Fuse S, Nakamura H, et al.
Photodiagnosis Photodyn Ther
. 2017 Oct;
20:238-245.
PMID: 29079353
Background: Subcellular localization of a photosensitizer is known to determine the therapeutic efficacy of photodynamic therapy (PDT). Cell membrane is an optimal target that promises an effective treatment outcome. Objectives:...
14.
Li S, Nishikawa T, Kaneda Y
Cancer Sci
. 2017 Sep;
108(12):2333-2341.
PMID: 28945328
We have already reported that the inactivated Sendai virus (hemagglutinating virus of Japan; HVJ) envelope (HVJ-E) has multiple anticancer effects, including induction of cancer-selective cell death and activation of anticancer...
15.
Lee C, Nishikawa T, Kaneda Y
Oncotarget
. 2017 May;
8(21):35048-35060.
PMID: 28456782
Salmonella can target to tumor microenvironments after systemic treatment. The hemagglutinating virus of Japan-envelope (HVJ-E) induced apoptosis in tumor cells without toxicity in normal cells. Current HVJ-E therapeutic strategies, aimed...
16.
Chang C, Tai J, Li S, Nishikawa T, Kaneda Y
Oncotarget
. 2016 Jun;
7(27):42195-42207.
PMID: 27259252
The tumor microenvironment (TME) fosters tumors by attenuating anti-tumor immunity, reinforcing tumor cell survival and increasing angiogenesis. Among the constituents of the TME, here, we focused on tumor-associated neutrophils (TANs)....
17.
Li Y, Nishikawa T, Kaneda Y
Sci Rep
. 2016 Apr;
6:25077.
PMID: 27117228
Tumours constitute unique microenvironments where various blood cells and factors are exposed as a result of leaky vasculature. In the present study, we report that thrombin enrichment in B16F10 melanoma...
18.
Liu L, Nishikawa T, Kaneda Y
Mol Ther
. 2015 Nov;
24(1):135-45.
PMID: 26548591
Inactivated Sendai virus (hemagglutinating virus of Japan; HVJ) envelope (HVJ-E) induces anticancer immunity and cancer cell-selective apoptosis through the recognition of viral RNA genome fragments by retinoic acid-inducible gene-I (RIG-I)....
19.
Nishikawa T, Tung L, Kaneda Y
Mol Ther
. 2014 Jul;
22(12):2046-2055.
PMID: 25023327
Tumor microenvironments include a number of fibrin clots due to the microbleeding caused by cancer cell invasion into blood vessels, which suggests the potential utility of a platelet vector for...
20.
Matsushima-Miyagi T, Hatano K, Nomura M, Li-Wen L, Nishikawa T, Saga K, et al.
Clin Cancer Res
. 2012 Sep;
18(22):6271-83.
PMID: 23014529
Purpose: The treatment of cancer with oncolytic viruses primarily depends on the selective viral replication in cancer cells. However, a replication-incompetent hemagglutinating virus of Japan (HVJ; Sendai virus) envelope (HVJ-E)...